CommercialCoverageMedium impact
Electrical Stimulation for Nausea, Vomiting, Motion Sickness and Other Selected Indications (CPB 0676, reviewed 2025-10-07)
Aetna·OB-GYN, Oncology, General Surgery +2 more·Medical Policy
Effective date
Oct 7, 2025
We identified it
Aug 14, 2026
Summary
Aetna updated its policy on transcutaneous electrical acupoint stimulation (TEAS) devices, establishing that prescription ReliefBand and PrimaBella are NOW COVERED for post-operative nausea, chemotherapy-induced nausea unresponsive to antiemetics, and hyperemesis gravidarum unresponsive to conservative therapy. Over-the-counter ReliefBand for motion sickness remains non-covered. Extensive list of other TEAS indications are classified as experimental/investigational and not covered.
Action Required
By October 7, 2025: Billing team must implement the following in billing system and encounter workflows: (1) Code E0765 (nerve stimulator for nausea/vomiting) is NOW COVERED when documented with medical necessity for post-operative nausea (K91.0), chemotherapy-induced nausea (T45.1X5A-S with documentation of antiemetic failure), or hyperemesis gravidarum (O21.0-O21.9 with documentation of failed conservative therapy); (2) CPT codes 97813, 97814 are NOT covered for any TEAS indications listed in experimental section; (3) HCPCS codes E0721, A4543, S8930 (Sparrow Ascent and auricular TEAS) are NOT covered; (4) CPT codes 0783T, 97014, 97032 require prior authorization review and documentation of medical necessity before billing; (5) OTC ReliefBand claims remain denied - flag for patient education. Update denial templates and prior auth requirements in system. Claims submitted without proper documentation of failed conservative therapy will be denied. Providers must document antiemetic failure or conservative therapy failure in medical record. Front desk should educate patients that prescription devices only are covered.